Physician profile

Rachel Rexing-Thacker

Optometrist · Evansville, IN

NPI 1437641354

$882.02

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$38.27

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alcon Vision LLC $340.58 2019-2022
Bausch & Lomb, A Division of Bausch Health US, LLC $123.48 2019
Biotissue Holdings INC. $120.16 2021
Sun Pharmaceutical Industries INC. $74.04 2020-2022
Aerie Pharmaceuticals, INC. $62.47 2021
Glaukos Corporation $55.82 2021
Novartis Pharmaceuticals Corporation $53.66 2021-2023
Shire North American Group INC $32.41 2019
Carl Zeiss Meditec Ag $19.40 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rachel Rexing-Thacker

$882.02

in general payments reported 2019-2025

Years
2019-2023
Top company
Alcon Vision LLC

https://glasscript.com/doctor/4625476/rachel-rexing-thacker

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.